Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

September 6, 2012

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

According to the , lung cancer is the number one cause of cancer deaths in men and women each year. The current standard treatment for advanced NS-NSCLC patients, the most common form of advanced NSCLC, is either Pac+Cb+B or pemetrexed plus cisplatin. This trial sought to define a new standard of care by comparing Pac+Cb+B to the experimental Pem+Cb+B to determine if either improved overall survival for late-stage . Pemetrexed plus cisplatin was not tested in this trial.

The 939 patients were randomized to receive one of the two treatment arms every three weeks for up to four cycles. The patients received the same arm for each cycle. Overall survival was not statistically different between the two arms, 12.6 months in Pem+Cb+ Bev versus 13.4 months for the Pac+Cb+B arm, The experimental arm of Pem+Cb+Bev led to a increase in time before progression of disease (PFS) compared with the standard arm of Pac+ Cb+Bev—6 months versus 5.6 months, respectively.

"The fact that there was no improvement in survival with the experimental regimen was disappointing, but these findings are important as we continue to navigate ways to improve survival for this devastating disease," said Jyoti Patel, MD, lead author of the study and an associate professor in Medicine-Hematology/Oncology at Northwestern University in Chicago. "It is important to note that both regimens demonstrated tolerability, although their toxicities differed. These differences can be important for our patients."

Explore further: Adding bavituximab to second-line chemotherapy doubles response rate

Related Stories

Adding bavituximab to second-line chemotherapy doubles response rate

September 6, 2012
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...

Brain radiation after lung cancer treatment reduces risk of cancer spreading

September 6, 2012
Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); ...

Stage I NSCLC patients who receive radiation therapy are surviving longer

September 6, 2012
Stage I, non-small cell lung cancer (NSCLC) patients who received radiation therapy have an increased median survival of 21 months compared to 16 months, and the percentage of patients who receive no treatment declined from ...

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Powerful drug combo gangs up to tackle triple-negative breast cancer

September 26, 2017
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death.

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.